Skip to main content

Tweets

GLP-1 Keeps on Working in PsA Dr. David Liew | Abstract 2942 | ACR 2026 https://t.co/9lzyNq0RyS https://t.co/E7gjUj6Tgx
Dr. John Cush @RheumNow ( View Tweet )
3 hours 12 minutes ago
New FDA Approved for Polymyalgia Rheumatica - Secukinumab The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Dr. John Cush @RheumNow ( View Tweet )
4 hours 11 minutes ago
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
Dr. John Cush @RheumNow ( View Tweet )
5 hours 11 minutes ago
Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections At #ACR26, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR-based therapies. https://t.co/qYWKJtTxmZ
Dr. John Cush @RheumNow ( View Tweet )
6 hours 42 minutes ago
One dose for every body? Rethinking drug exposure Dr. Jiha Lee | Size Matters Session | ACR 2026 https://t.co/zodmhAZm1e https://t.co/kkBrQNmwXW
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Top 6 Practice-Changing Highlights from ACR26 The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance. Here is our https://t.co/JmRpPh8Wzi
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Does a Gout Flare Increase Risk of a Cardiovascular Event? In 2022, Cipolletta and colleagues published a JAMA study showing a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the https://t.co/G91c9oz7tP
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Who benefits from GLP-1s in your rheumatology clinic? Hear Dr. Catherine Bakewell tackle that question on Jan 30 at https://t.co/9THCAABeZ0. Kick off 2027 with rheumatology CME Jan 30–31 in Irving, TX, or live online. Early-bird pricing through Dec 15. https://t.co/xjuAWKqAY9 https://t.co/9Nwx85xIb6
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Low PREVENT Score, Real Risk: Coronary Calcium and Heart Failure in Lupus Dr. Akhil Sood | Abstracts 2861 0922 | ACR 2026 https://t.co/hREBmSbDQK https://t.co/wuiriT45zs
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Who gets left behind by the new SpA Criteria Dr. Henrique Dalmolin & Dr. Carla Saad & Dr. Licia Mota | ACR 2026 https://t.co/SJhUVCZ8aZ https://t.co/vpe7ASo82Q
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Biologics vs JAKi: MACE and VTE Risk in PsA Dr. Sheila Reyes & Dr. Marina Magrey | Abstract 2304 | ACR 2026 https://t.co/IzafHHg9Me https://t.co/PGfQOk882R
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
JAKi CV Safety in Younger Adults https://t.co/Cp7YEz0277 https://t.co/oBGRQjBuoH
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
UPSTAND study: widespread pain responding to JAK inhibition https://t.co/ZGouZSXaXU https://t.co/He2nXncsFF
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Who might benefit from GLP-1s in your rheumatology clinic? Join Drs. Catherine Bakewell and Leonard Calabrese at https://t.co/9THCAABeZ0, Jan 30–31 in Dallas, TX, or live online. Kick off 2027 with 12.5 CME credits. Early bird pricing through Dec 15. https://t.co/xjuAWKqAY9 https://t.co/xhqg94lmoy
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Pioneers & Progress in Pediatric Rheumatology: The 50th Anniversary Dr. Susan Shenoi | "Mastering the Field of Pediatric Rheumatology: Pioneers and Progress, 50th Anniversary" |ACR 2026 https://t.co/hSx8LHR99s https://t.co/cQNLQkT6qp
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
×